For research use only. Not for therapeutic Use.
Budigalimab（Cat No.:I042148）is an experimental monoclonal antibody targeting PD-1 (programmed cell death protein 1), a checkpoint inhibitor that plays a role in suppressing the immune response. By blocking PD-1, budigalimab helps to enhance the immune system’s ability to recognize and attack cancer cells. It is being investigated in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and head and neck cancers. Budigalimab aims to provide an alternative or complement to existing immune checkpoint inhibitors, with the potential to improve patient outcomes.
| Catalog Number | I042148 |
| CAS Number | 2098225-93-3 |
| Purity | ≥95% |
